GlassScriptPhysician profile
Jeffrey Lawrence Oconnor
NPI 1528011830
$7,414.01
in general payments reported to CMS, 2019-2025
48 companies · $3,250 in 2025
The $3,250 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $359 · 2021: $763 · 2022: $882 · 2023: $847 · 2024: $676 · 2025: $3,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,600 · Food and Beverage: $2,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,599.99 |
| Food and Beverage | $2,173.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,500.00 | 2025 | |
| Pfizer INC. | $836.09 | 2019-2025 | |
| Astellas Pharma US INC | $589.86 | 2019-2024 | Xtandi, Myrbetriq |
| Myriad Genetic Laboratories, INC. | $318.67 | 2021-2025 | Prolaris |
| Sumitomo Pharma America, INC. | $253.90 | 2023-2025 | Gemtesa, Orgovyx |
| Myovant Sciences INC. | $228.10 | 2022 | |
| Axonics, INC. | $225.56 | 2020-2023 | Bulkamid |
| Abbvie INC. | $188.05 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $145.12 | 2019-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $136.56 | 2019-2022 | |
| Antares Pharma, INC. | $134.38 | 2019-2025 | Xyosted |
| Coloplast Corp | $128.34 | 2020-2022 | |
| Blue Earth Diagnostics | $118.67 | 2019-2021 | |
| Urovant Sciences INC | $113.54 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $112.72 | 2020-2025 | Keytruda |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Oconnor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.